Author: [email protected]

Release – FEVO Adds Harte Hanks as Official CX Partner

Posted on by [email protected]

Research, News, and Market Data on HHS

CHELMSFORD, MA / ACCESSWIRE / September 15, 2022 / Harte Hanks Inc. (Nasdaq:HHS), a leading global customer experience company focused on bringing companies closer to customers for nearly 100 years, and FEVO, a leading social-commerce technology company that lets friends shop together, announced a growing partnership today. The partnership is designed to help FEVO maintain its fan-and client-first ethos, as FEVO builds upon its explosive growth from 2021.

The partnership expands Harte Hanks’ prior successful work with FEVO to now allow Harte Hanks to serve as FEVO’s exclusive CX partner. The exclusivity of this relationship demonstrates FEVO’s belief in the power of best-in-class customer care that Harte Hanks provides, and the value it brings to their clients. Currently, Harte Hanks provides a range of services in support of FEVO, including client support, ticket fulfillment and back-office support.

“We’re excited to partner with Harte Hanks as we keep the focus on the fans and brands who trust FEVO with their purchases,” said Betty Tran, FEVO Chief Marketing Officer. “To enhance our customer experience as our consumer base continues to grow, we look forward to introducing Harte Hanks’ services to FEVO partners in need.”

“This expansion of the partnership between Harte Hanks and FEVO demonstrates the strength and value already realized in our work together,” said Ben Chacko, Harte Hanks Customer Care Managing Director. “Our goal is to maximize satisfaction during all interactive communications with FEVO clients and customers.”

For more information visit: https://www.hartehanks.com/

About Harte Hanks:

Harte Hanks (Nasdaq:HHS) is a leading global customer experience company whose mission is to partner with clients to provide them with CX strategy, data-driven analytics and actionable insights combined with seamless program execution to better understand, attract and engage their customers.

Using its unparalleled resources and award-winning talent in the areas of Customer Care, Fulfillment and Logistics, and Marketing Services, Harte Hanks has a proven track record of driving results for some of the world’s premier brands, including Bank of America, GlaxoSmithKline, Unilever, Pfizer, HBOMax, Volvo, Ford, FedEx, Midea, Sony and IBM, among others. Headquartered in Chelmsford, Massachusetts, Harte Hanks has over 2,500 employees in offices across the Americas, Europe and Asia Pacific.

About FEVO:

FEVO is dedicated to changing e-commerce: Our proprietary technology adds friend power to a brand’s site for more browsing, more fun – and more sales. We enable consumers to invite friends to purchase together with just a few clicks, allowing groups to connect and communities to form. And it all happens on a brand’s site with just one single line of code, so brands can capture more data while building their own social graphs and identifying valuable customers.

For media inquiries or further information, please contact: [email protected]

FEVO Media Contact: [email protected]

SOURCE: Harte Hanks, Inc.

Release – Comtech Awarded London Police Service Next Generation 9-1-1 Contract

Posted on by [email protected]

Research, News, and Market Data on CMTL

MELVILLE, N.Y.–(BUSINESS WIRE)–Sep. 15, 2022– September 15, 2022– Comtech (NASDAQ: CMTL) announced today that Comtech Solacom Technologies, Inc., a division of the Company’s 9-1-1 Public Safety and Security segment, was recently awarded a Next Generation 9-1-1 (“NG9-1-1”) services contract to provide its Guardian call management solution to the London Police Services. The London Police Service is Comtech Solacom’s latest customer in the Southern Ontario region, joining the Toronto Paramedic and Toronto Police Services, which also recently awarded contracts to Comtech Solacom. The new system award includes multiple years of support and comprehensive cybersecurity protection.

The public safety answering point (“PSAP”) will receive a geo-diverse, redundant NG9-1-1 Guardian Call Management solution fully equipped with Guardian Intelligent Workstations (“IWS”). IWS’ are powerful emergency call taking positions designed to maximize call management effectiveness. The intuitive user interface allows call takers to quickly assess, prioritize and handle landline, wireless and VoIP calls. Call takers can quickly create multi-party conferences, transfer calls, determine the location of callers and play back recently recorded conversations. The Guardian IWS is also engineered to be future proof so that next generation capabilities such as real-time text (RTT), exchanging video, images and data with specially trained staff can be supported once they become available to the public. In addition, the system is designed according to industry standards and the Canadian Radio-Television and Telecommunication (“CRTC”) Next Generation 9-1-1 directives.

“We were impressed with many of the advanced, next generation features inherent to the Guardian call management platform including Mapping and Text-from-911,” said Stu Betts, Deputy Chief of the London Police Service. “The added service of safeguarding our network from cyberattacks was imperative and Comtech Solacom understood that need and offered us a solution that met our exact requirements.”

“We’re pleased to be partnering with the London Police Services Board as we deploy a complete, turnkey next generation Guardian call management solution to the London Police Service,” said Ken Peterman, President and CEO of Comtech. “With their new Guardian solution, the London Police Service will be able to modernize current 911 operations, improve public safety services and get piece of mind knowing they’re protected from potential cybersecurity threats.”

About Comtech

Comtech Telecommunications Corp. is a leading global provider of next-generation 911 emergency systems and secure wireless communications technologies to commercial and government customers around the world. Headquartered in Melville, New York and with a passion for customer success, Comtech designs, produces and markets advanced and secure wireless solutions. For more information, please visit www.comtech.com.

Forward-Looking Statements

Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results could differ materially from such forward-looking information. The Company’s Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward-looking information in this press release is qualified in its entirety by the risks and uncertainties described in such Securities and Exchange Commission filings.

PCMTL

Investor Relations
Robert Samuels
631-962-7102
[email protected]

Source: Comtech Telecommunications Corp.

Release – Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) for the Prevention of Rejection in Allograft and Xenograft Transplantation in Animal Models at the International Congress of The Transplantation Society (TTS 2022)

Posted on by [email protected]

Research, News, and Market Dat on TNXP

September 15, 2022 7:00am EDT

TNX-1500 Treatment Prevents Organ Rejection and Preserves Function for Both Allograft and Xenograft Transplants in Animal Studies

CHATHAM, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced data from three oral presentations by faculty at the Center for Transplantation Sciences, Massachusetts General Hospital Center at the 29th International Congress of The Transplantation Society (TTS 2022) held September 10-14, 2022 in Buenos Aires, Argentina. The data involve studies of Tonix’s TNX-1500 (Fc modified anti-CD40L monoclonal antibody) product candidate in development for the prevention of organ transplant rejection. The molecular target of TNX-1500 is CD40-ligand (CD40L), which is also known as CD154. Copies of the presentations are available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com.

The presentations titled, “Long-term rejection-free renal allograft survival with Fc-modified anti-CD154 antibody monotherapy in nonhuman primates,” and “Monotherapy with TNX-1500, a Fc-modified anti-CD154mAb, prolongs cardiac allograft survival in cynomolgus monkeys,” include data demonstrating that TNX-1500 treatment showed activity in preventing organ rejection and was well tolerated in non-human primates. Blockade of CD40L with TNX-1500 monotherapy consistently and safely prevented pathologic alloimmunity in non-human primate cardiac and kidney allograft models without clinical thrombosis.

The presentation titled, “Long-term (>1 year) rejection-free survival of kidney xenografts with triple xenoantigen knockout and multiple human transgenes in nonhuman primates,” includes data demonstrating that TNX-1500 treatment showed activity in preventing xenograft kidney rejection and was well tolerated in non-human primates. Xenografts are transplanted organs from donors of a different species from the recipient, and in this study, the xenografts originated from genetically engineered pigs. Blockade of CD40L with TNX-1500 monotherapy consistently and safely prevented pathologic xenoimmunity in non-human primate kidney xenograft models without clinical thrombosis.

“There remains a significant need for new treatments with improved activity and tolerability to prevent organ transplant rejection,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “To date, there has not been a humanized anti-CD40L antibody that can effectively prevent transplant rejections with an acceptable level of tolerability. TNX-1500 is a third generation anti-CD40L mAb that has been designed by protein engineering to decrease FcγRII binding and to reduce the potential for thrombosis. The animal studies found that TNX-1500 retains activity to prevent rejection and preserve graft function. We believe TNX-1500 has the potential for treating and preventing organ transplant rejection in both allograft and xenograft transplants. Tonix expects to initiate a Phase 1 trial of TNX-1500 in the first half of 2023. Preventing transplant rejection is the first indication we are pursuing, but based on results of anti-CD40L in numerous animal models, we believe that TNX-1500 has the potential for treating a number of autoimmune conditions.”

Tonix Pharmaceuticals Holding Corp.*

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022 and interim data expected in the second quarter of 2023. TNX-102 SL is also being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix initiated a Phase 2 study in Long COVID in the third quarter of 2022 and expects interim data in the first half of 2023. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy designation by the FDA. A Phase 2 study of TNX-1300 is expected to be initiated in the first quarter of 2023. TNX-1900 (intranasal potentiated oxytocin), a small molecule in development for chronic migraine, is expected to enter the clinic with a Phase 2 study in the fourth quarter of 2022. Tonix’s rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan Drug designation by the FDA. Tonix’s infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox, next-generation vaccines to prevent COVID-19, and a platform to make fully human monoclonal antibodies to treat COVID-19. TNX-801, Tonix’s vaccine in development to prevent smallpox and monkeypox, also serves as the live virus vaccine platform or recombinant pox vaccine (RPV) platform for other infectious diseases. A Phase 1 study of TNX-801 is expected to be initiated in Kenya in the first half of 2023. Tonix’s lead vaccine candidate for COVID-19 is TNX-1850, a live virus vaccines based on Tonix’s recombinant pox live virus vector vaccine platform. A Phase 1 study of the COVID-19 vaccine is expected to be initiated in the second half of 2023.

*All of Tonix’s product candidates are investigational new drugs or biologics and have not been approved for any indication.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2022, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Contacts

Jessica Morris (corporate)
Tonix Pharmaceuticals
[email protected]
(862) 904-8182

Olipriya Das, Ph.D. (media)
Russo Partners
[email protected]
(646) 942-5588

Peter Vozzo (investors)
ICR Westwicke
[email protected]
(443) 213-0505

Source: Tonix Pharmaceuticals Holding Corp.

Released September 15, 2022

Release – MustGrow and Global Partners Drive Biological Programs Forward

Posted on by [email protected]

Research, News, and Market Data on MGROF

  • Soil biofumigation platform continues to show promising results across multiple continents.
  • Postharvest activities in potatoes, fruits and vegetables have demonstrated initial efficacy and work is now focused on application, timing, dose rates and residues.
  • Bioherbicide optimization and formulation work advances.

Saskatoon, Saskatchewan–(Newsfile Corp. – September 15, 2022) – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company” or “MustGrow“), and its global agriculture partners continue to drive MustGrow’s organic mustard-derived crop protection and food preservation technology forward through field trials, development work and regulatory approval strategies in key global agricultural regions. Publicly-disclosed programs include:

  • Sumitomo Corporation

Exclusive evaluation agreement in the Americas for preplant soil fumigation, bioherbicide, postharvest and food preservation for potatoes and bananas. Sumitomo Corporation is funding and driving all field development, including toxicology, safety, efficacy, and regulatory work necessary for commercialization. (Press release link)

  • Bayer

Exclusive evaluation agreement in Europe, Asia Pacific, Middle East and Africa for preplant soil fumigation, bioherbicide applications and postharvest food preservation of potatoes including sprout inhibition. The first year of the evaluation is focused on the pre-plant soil fumigant application. Bayer is funding and driving all laboratory, field, regulatory, and market assessments in the target regions. (Press release link)

  • Janssen PMP, a division of Johnson & Johnson-owned Janssen Pharmaceutica NV

Global exclusive evaluation agreement for postharvest storage preservation of fruits and vegetables, excluding grains, potatoes, bananas and shipping container fumigation. Janssen PMP is funding and driving all application testing and development work. (Press release link)

  • NexusBioAg, a division of Univar Solutions

Exclusive marketing and distribution agreement in Canada for canola (clubroot disease) and pulse crops (aphanomyces disease). NexusBioAg is funding and driving all field development and regulatory work necessary for commercialization. (Press release link)

———

GLOBAL PROGRAM ADVANCEMENTS:

Soil Biofumigation
Sumitomo Corporation has continued to generate data across multiple crops, evaluating application timing, methods, and dose rates. Efficacy data generated across multiple countries and programs remains positive and has already resulted in new country expansions and program extension. MustGrow and Sumitomo Corporation are continually assessing market opportunities for further regional and application expansions. Utilizing MustGrow’s platform technology, Sumitomo Corporation currently has field trials and regulatory development work ongoing in the US, Mexico, and Chile.

In the US, EPA product registration work continues to advance, with Sumitomo Corporation playing a pivotal role in the registration approval process. In addition, Mexico registration work is progressing forward, as there have now been two consecutive years of successful field trials with Sumitomo Corporation. Mexico is a key global agriculture region both in size and strategic location. In Chile, registration work has commenced with the country approving an Experimental Use Permit to Sumitomo Corporation and MustGrow for field testing and registration activities.

Bayer’s initial laboratory and greenhouse studies utilizing MustGrow’s mustard-derived technology have been promising. Building on these positive results, Bayer and MustGrow have new trials underway and further studies planned across Europe, Asia and Africa. Bayer is evaluating registration pathways for multiple regions.

Building on their 2021 field trial program for treatment of canola (clubroot disease) and pulse crops (aphanomyces disease), NexusBioAg and MustGrow signed an Exclusive Marketing and Distribution Agreement in Canada. NexusBioAg intends to trial MustGrow’s technology in its 2023 BioAg Advantage program (“BAT“), which are wide-scale field trials conducted at the farmer level. NexusBioAg leverages its BAT program to introduce new and exciting potential ‘portfolio’ products to large Canadian farmers.

Postharvest Food Preservation
Harnessing MustGrow’s mustard-derived biological agent as a postharvest fruit and vegetable application, Janssen PMP has demonstrated initial success in decay, fungal, and bacterial disease efficacy. Advancing to the next stage, Janssen PMP’s testing program will focus on phytotoxicity, residues, application rates, application methods and dose timing. As food preservation is a critical global issue, reducing postharvest fruit and vegetable losses could substantially increase worldwide food availability.

MustGrow had previously tested its organic mustard-based technology and outperformed leading synthetic chemical standards for treatment of stored potatoes for both Fusarium dry rot disease and sprouting. No disease/sprouting combination solutions currently exist in the marketplace, making MustGrow’s application unique in addressing both issues simultaneously. Leading sprout inhibiter chlorpropham (CIPC) had been banned by the European Union as of Oct. 8, 2020. Sumitomo Corporation is advancing this program in the US with trials and data review ongoing.

Bioherbicide
MustGrow’s bioherbicide program is now focused on extraction optimization and formulation work. Perfomance and efficacy knowledge utilizing the mustard-derived Thiocyanate molecule, both internally and externally, has demonstrated potential impact as both a stand alone and combination herbicide in multiple markets. MustGrow is focused on production parameters, improving formulations for application flexibility, and the potential to combine MustGrow’s bioherbicide with leading chemicals.

———

About MustGrow
MustGrow is an agriculture biotech company developing organic biopesticides and bioherbicides by harnessing the natural defense mechanism of the mustard plant to protect the global food supply from diseases, insect pests, and weeds. MustGrow and its leading global partners — Janssen PMP (pharmaceutical division of Johnson & Johnson), Bayer, Sumitomo Corporation, and Univar Solutions’ NexusBioAg — are developing mustard-based organic solutions to potentially replace harmful synthetic chemicals. Over 100 independent tests have been completed, validating MustGrow’s safe and effective approach to crop and food protection. Pending regulatory approval, MustGrow’s patented liquid products could be applied through injection, standard drip or spray equipment, improving functionality and performance features. Now a platform technology, MustGrow and its global partners are pursuing applications in several different industries from preplant soil treatment and weed control, to postharvest disease control and food preservation. MustGrow has approximately 49.2 million basic common shares issued and outstanding and 55.6 million shares fully diluted. For further details, please visit www.mustgrow.ca.

ON BEHALF OF THE BOARD

“Corey Giasson”

Director & CEO
Phone: +1-306-668-2652
[email protected]

MustGrow Forward-Looking Statements

Certain statements included in this news release constitute “forward-looking statements” which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.

Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved”. Examples of forward-looking statements in this news release include, among others, statements MustGrow makes regarding: (i) potential product approvals; (ii) anticipated actions by partners to drive field development work including dose rates, application frequency, application methods, and the regulatory work necessary for commercialization; (iii) expected product efficacy of MustGrow’s mustard-based technologies; and (iv) expected outcomes from collaborations with commercial partners.

Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) the preferences and choices of agricultural regulators with respect to product approval timelines; (ii) the ability of MustGrow’s partners to meet obligations under their respective agreements; and (iii) other risks described in more detail in MustGrow’s Annual Information Form for the year ended December 31, 2021 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available at www.sedar.com. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.

This release does not constitute an offer for sale of, nor a solicitation for offers to buy, any securities in the United States.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

© 2022 MustGrow Biologics Corp. All rights reserved.

Release – Schwazze Signs Definitive Documents To Acquire Certain Assets Of Lightshade Labs LLC

Posted on by [email protected]

Research, News, and Market Data on SHWZ

Continues to Go Deep, Adding to Retail Footprint in Colorado

DENVER, CO – September 14, 2022 – Schwazze, (OTCQX:SHWZ NEO:SHWZ) (“Schwazze” or the “Company”), announced that it has signed definitive documents to acquire certain assets of Lightshade Labs LLC (“Lightshade”). The proposed transaction includes the adult use Lightshade dispensaries located at 503 Havana St. in Aurora, as well as 2215 E. Mississippi Ave. in Denver’s vibrant Washington Park neighborhood. This acquisition continues Schwazze’s aggressive expansion in Colorado and upon close will bring the Company’s total number of Colorado dispensaries to 25.

The consideration for the proposed acquisition is US$2.75 million and will be paid as all cash. The acquisition is expected to close in the first quarter of 2023 after Colorado Marijuana Enforcement Division and local licensing approval.

“Schwazze is excited to add to our retail footprint in the greater Denver area, providing two additional retail locations to our existing 23 throughout Colorado. We look forward to extending our exceptional customer service and wide product selection to both new and existing customers in these new locations.” said Collin Lodge, Division President of Colorado.

Since April 2020, Schwazze has acquired or announced the planned acquisition of 35 cannabis dispensaries as well as seven cultivation facilities and two manufacturing assets in Colorado and New Mexico. In May 2021, Schwazze announced its BioSciences division and in August 2021 it commenced home delivery services in Colorado.

About Schwazze

Schwazze (OTCQX: SHWZ NEO: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale. The Company is committed to unlocking the full potential of the cannabis plant to improve the human condition. Schwazze is anchored by a high- performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector. Schwazze is passionate about making a difference in our communities, promoting diversity and inclusion, and doing our part to incorporate climate-conscious best practices. Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth.

Forward-Looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “plan,” “will,” “may,” “continue,” “predicts,” or similar words. Forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; (v) difficulties in securing regulatory approval to market our products and product candidates; (vi) our ability to successfully execute our growth strategy in Colorado and outside the state, (vii) our ability to consummate the acquisition described in this press release or to identify and consummate future acquisitions that meet our criteria, (viii) our ability to successfully integrate acquired businesses, including the acquisition described in this press release, and realize synergies therefrom, (ix) the ongoing COVID-19 pandemic, (x) the timing and extent of governmental stimulus programs, and (xi) the uncertainty in the application of federal, state and local laws to our business, and any changes in such laws. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.
 

Investors
Joanne Jobin
Investor Relations
[email protected]
647 964 0292		Media
Julie Suntrup, Schwazze
Vice President | Marketing & Merchandising
[email protected]
303 371 0387

Release – Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology

Posted on by [email protected]

Research, News, and Market Data on OCGN

September 14, 2022

  • Data include the persistence of immune responses and protection against variants of concern, especially Delta and Omicron
  • Ocugen has North American commercialization rights for BBV152, commercialized as COVAXIN™

MALVERN, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the publication “A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects” appeared in Frontiers in Immunology. BBV152, commercialized as COVAXIN™, is developed and manufactured by Ocugen’s partner Bharat Biotech, a global leader in vaccine innovation based in Hyderabad, India. BBV152 is currently authorized by the World Health Organization, authorized under Emergency Use Authorization in 28 countries, and accepted as a COVID-19 vaccine to travel into over 85 countries. It is under clinical investigation by Ocugen in the United States for use in adults aged 18 years and older.

This review by Dotiwala and Upadhyay provides a detailed analysis of the immunogenicity, safety, and efficacy of BBV152—a whole virus inactivated vaccine and an important tool in the fight to control the COVID-19 pandemic. Additionally, BBV152 has a broader impact on public health, as it induces high neutralization efficacy against different SARS-CoV-2 variants of concern.

“Unfortunately, the COVID-19 pandemic is not yet over, despite the introduction of effective vaccines and a greater understanding of COVID-19 pathogenesis and transmission dynamics,” said David Fajgenbaum, MD, MBA, MSc, Assistant Professor of Medicine, Translational Medicine & Human Genetics, University of Pennsylvania, and Ocugen Vaccine Scientific Advisory Board member. “This study demonstrates durability through immune memory and a broader immune response with BBV152 and provides further evidence that additional vaccine options—including those built on a traditional vaccine platform—are needed.”

Findings include:

  • 77.8% and 93.4% protection from symptomatic COVID-19 disease and severe symptomatic COVID-19 disease respectively.
  • Studies in pediatric populations show superior immunogenicity (geometric mean titer ratio of 1.76 compared to an adult) with a seroconversion rate of >95%.
  • Reactogenicity and safety profiles were comparable across all pediatric age groups between 2-18 yrs.

The study concludes that BBV152 is a suitable alternative to mRNA vaccines.

About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. 
Discover more at www.ocugen.com and follow us on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:

Tiffany Hamilton
Head of Communications
[email protected]

Release – Entravision Announces Participation in Upcoming Investor Conferences

Posted on by [email protected]

Research, News, and Market Data on EVC

SANTA MONICA, Calif.–(BUSINESS WIRE)– Entravision (NYSE: EVC), a leading global advertising solutions, media and technology company, today announced Chris Young, Chief Financial Officer and Treasurer, will present at the following upcoming investor conferences and meet with investors throughout the day:

  • The Deutsche Bank 30th Annual Leveraged Finance Conference to be held September 19-21, 2022 in Scottsdale, Arizona. Management is scheduled to present on Tuesday, September 20, 2022 at 11:20 a.m. PT.
  • The Sidoti September Small-Cap Conference to be held virtually September 21-22, 2022. Management is scheduled to present on Wednesday, September 21, 2022 at 12:15 p.m. PT.

The presentations will be webcast live over the Internet, and links to the live webcasts and replays will be available on Entravision’s Investor Relations website at investor.entravision.com.

About Entravision Communications Corporation

Entravision is a leading global advertising, media and ad-tech solutions company connecting brands to consumers by representing top platforms and publishers. Our dynamic portfolio includes digital, television and audio offerings. Digital, our largest revenue segment, is comprised of four business units: our digital sales representation business; Smadex, our programmatic ad purchasing platform; our branding and mobile performance solutions business; and our digital audio business. Through our digital sales representation business, we connect global media companies such as Meta, Twitter, TikTok and Spotify with advertisers in primarily emerging growth markets worldwide. Smadex is our mobile-first demand side platform, enabling advertisers to execute performance campaigns using machine learning. We also offer a branding and mobile performance solutions business, which provides managed services to advertisers looking to connect with global consumers, primarily on mobile devices, and our digital audio business provides digital audio advertising solutions for advertisers in the Americas. In addition to digital, Entravision has 49 television stations and is the largest affiliate group of the Univision and UniMás television networks. Entravision also manages 45 primarily Spanish-language radio stations that feature nationally recognized, Emmy award-winning talent. Shares of Entravision Class A Common Stock trade on the NYSE under ticker: EVC. Learn more about our offerings at entravision.com or connect with us on LinkedIn and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005264/en/

Christopher T. Young
Chief Financial Officer
Entravision
310-447-3870

Kimberly Esterkin
Addo Investor Relations
310-829-5400
[email protected]

Source: Entravision Communications Corporation

Release – The Gevo NW Iowa RNG Project Achieves Important EPA Milestone Ahead of Schedule

Posted on by [email protected]

Research, News, and Market Data on GEVO

ENGLEWOOD, Colo., Sept. 13, 2022 (GLOBE NEWSWIRE) — Gevo, Inc. (NASDAQ: GEVO) is pleased to announce that its Northwest Iowa Renewable Natural Gas project, Gevo NW Iowa RNG, LLC (Gevo RNG), was granted registration approval by the Environmental Protection Agency (EPA), allowing Gevo RNG to participate in the Renewable Fuel Standard (RFS) program.

Gevo previously estimated that approval for RFS Renewable Identification Numbers (RINS) through RFS and carbon credits through California’s Low Carbon Fuel Standard (LCFS) program would happen in late 2022 or early 2023. This early approval is a result of the quality work by Gevo’s expert operations, sustainability, and compliance teams as well as Gevo’s dedicated project partners.

“The work we are doing at the Northwest Iowa RNG operations is critical to Gevo’s work in the reduction of the carbon intensity of fuels. While Gevo RNG is just one piece of the circular economy that Gevo is building, the capture of manure to make RNG in the production of transportation fuels is a very important component, said Dr. Chris Ryan, President and Chief Operating Officer at Gevo, Inc. Meeting the EPA registration requirements ahead of schedule is the direct result of the efforts of a dedicated team of hard-working individuals who demonstrate our collective commitment to this mission.”

The RNG Project generates renewable natural gas captured from dairy cow manure. The manure for the RNG Project is supplied by three dairy farms located in Northwest Iowa totaling over 20,000 milking cows. At full operational capacity, the RNG Project is expected to generate approximately 355,000 MMBtu of RNG per year, which is marketed by BP Canada Energy Marketing Corp. and BP Products North America Inc. (collectively, “bp”) in California on behalf of Gevo.

About Gevo
Gevo’s mission is to transform renewable energy and carbon into energy-dense liquid hydrocarbons. These liquid hydrocarbons can be used for drop-in transportation fuels such as gasoline, jet fuel and diesel fuel, that when burned have the potential to yield net-zero greenhouse gas emissions when measured across the full life cycle of the products. Gevo uses low-carbon renewable resource-based carbohydrates as raw materials, and is in an advanced state of developing renewable electricity and renewable natural gas for use in production processes, resulting in low-carbon fuels with substantially reduced carbon intensity (the level of greenhouse gas emissions compared to standard petroleum fossil-based fuels across their life cycle). Gevo’s products perform as well or better than traditional fossil-based fuels in infrastructure and engines, but with substantially reduced greenhouse gas emissions. In addition to addressing the problems of fuels, Gevo’s technology also enables certain plastics, such as polyester, to be made with more sustainable ingredients. Gevo’s ability to penetrate the growing low-carbon fuels market depends on the price of oil and the value of abating carbon emissions that would otherwise increase greenhouse gas emissions. Gevo believes that its proven, patented technology enabling the use of a variety of low-carbon sustainable feedstocks to produce price-competitive low-carbon products such as gasoline components, jet fuel and diesel fuel yields the potential to generate project and corporate returns that justify the build-out of a multi-billion-dollar business.

Gevo believes that the Argonne National Laboratory GREET model is the best available standard of scientific-based measurement for life cycle inventory or LCI.

Learn more at Gevo’s website: www.gevo.com

Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to a variety of matters, without limitation, including Gevo RNG, the EPA registration approval, Gevo’s production of renewable natural gas, and other statements that are not purely statements of historical fact. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Gevo and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Gevo undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Gevo believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gevo in general, see the risk disclosures in the Annual Report on Form 10-K of Gevo for the year ended December 31, 2021, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the U.S. Securities and Exchange Commission by Gevo.

Media Contact
Heather L. Manuel
+1 303-883-1114
[email protected]

Release – Kratos’ Mixed Reality Mission Readiness Training System Named a Finalist for The Halldale Group’s 2022 Military Simulation & Training Awards

Posted on by [email protected]

Research, News, and Market Data on KTOS

September 13, 2022 at 8:00 AM EDT

Nomination is in the Outstanding Immersive Technology Category

SAN DIEGO, Sept. 13, 2022 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a leading National Security Solutions provider, announced today that it has been named a finalist in Halldale Group’s 2022 Military Simulation and Training Awards. The award nomination reinforces Kratos’ leadership in the application of advanced immersive technologies to enhance military training.

Named in the Outstanding A/M/V/XR Application category Kratos was nominated for the Mixed Reality (MR) Mission Readiness Training (MRT) system it developed and fielded for Air Force Global Strike Command (AFGSC). MRT is a turn-key solution that enables aircrews to train in a containerized immersive environment consisting of a UH-1N Aircraft Simulator, Ground Party Simulator and Instructor Operator Station. The Aircraft Simulator is a high-fidelity replication of the cockpit, rear cabin, and simulated crew-served weapons enclosed in a Kratos mixed reality Holodeck.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/08e4c773-558b-41a6-ad10-0bbd97ae39cd

The Ground Party Simulator, also a containerized immersive environment, is fully integrated with the Aircraft Simulator, enabling ground forces to seamlessly join the collective training mission with their aircrews just as they would engage together in real combat situations. With full mission rehearsal capability, the MRT system has doubled combat mission readiness rates and is certified for both qualification and currency training of AFGSC security forces.

Commenting on being named a finalist in MS&T’s prestigious annual awards program, Jose Diaz, Sr. Vice President, Kratos Training Solutions, said that: “Making immersive technology a key awards category reflects the transformative impact this technology is having on military training. Kratos is pleased to be in the vanguard of this training evolution.”

Halldale Group’s MS&T Magazine’s Simulation and Training Awards Program showcases the people, products, processes, and organizations that provide exceptional value to its military clients. Many metrics are used to describe value, but the underlying principle is that value ultimately resides in how well clients are enabled to achieve their goals. Value is about outcomes and is often expressed in terms of change in areas such as resource use, effectiveness, efficiency, time, access, readiness or even capability.

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms and systems for United States National Security related customers, allies and commercial enterprises. Kratos is changing the way breakthrough technology for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research and streamlined development processes. At Kratos, affordability is a technology and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training, combat systems and next generation turbo jet and turbo fan engine development. For more information go to www.KratosDefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 26, 2021, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:
Yolanda White
858-812-7302 Direct

Investor Information:
877-934-4687
[email protected]

Kratos’ UH-1 Multi-Position Aircrew Virtual Environment Trainer (MP-AVET) enclosed in a Kratos mixed reality holodeck

 

Kratos’ UH-1 Multi-Position Aircrew Virtual Environment Trainer (MP-AVET) enclosed in a Kratos mixed reality holodeck

Source: Kratos Defense & Security Solutions, Inc.

Release – Eagle Bulk Shipping Inc. Adds Capacity – Acquires Modern Ultramax Bulkcarrier

Posted on by [email protected]

Research, News, and Market Data on EGLE

September 13, 2022 at 8:00 AM EDT

STAMFORD, Conn., Sept. 13, 2022 (GLOBE NEWSWIRE) — Eagle Bulk Shipping Inc. (NASDAQ: EGLE) (“Eagle Bulk,” “Eagle” or the “Company”), one of the world’s largest owner-operators within the midsize drybulk vessel segment, today announced that it has expanded its fleet with the purchase of a high-specification 2015-built scrubber-fitted Ultramax bulkcarrier for USD 27.5 million.

The vessel, which was constructed at Imabari Shipbuilding Co., Ltd. in Japan, will be renamed the M/V Tokyo Eagle and deliver to the Company during the fourth quarter of 2022.

As previously disclosed, the Company closed on the sale of the M/V Cardinal (2004-built non-scrubber fitted Supramax) in August 2022. The vessel was sold for USD 15.8 million and delivered just prior to her statutory drydock due date.

Following these transactions, Eagle’s fleet will total 53 ships (91% scrubber-fitted) with an average age of 9.5 years.   Since the Company commenced its vessel renewal and growth program, it has executed 51 S&P transactions, acquiring 30 modern vessels and divesting 21 of its oldest and least efficient ships. These sale and purchase transactions have enabled the Company to grow, while vastly improving overall fleet makeup; in terms of maintaining an attractive age profile, increasing cargo capacity per vessel, and reducing emissions on a per deadweight ton basis.

About Eagle Bulk Shipping Inc.
Eagle Bulk Shipping Inc. (“Eagle” or the “Company”) is a U.S. based fully integrated, shipowner-operator providing global transportation solutions to a diverse group of customers including miners, producers, traders, and end users. Headquartered in Stamford, Connecticut, with offices in Singapore and Copenhagen, Eagle focuses exclusively on the versatile midsize drybulk vessel segment and owns one of the largest fleets of Supramax/Ultramax vessels in the world. The Company performs all management services in-house (including: strategic, commercial, operational, technical, and administrative) and employs an active management approach to fleet trading with the objective of optimizing revenue performance and maximizing earnings on a risk-managed basis. For further information, please visit our website: www.eagleships.com.

CONTACT

Company:
Eagle Bulk Shipping, Inc.
[email protected]
+1 203 276 8100

Media:
ICR, Inc.
[email protected]
+1 203 682 8396

Source: Eagle Bulk Shipping Inc.

Release – Sierra Metals Announces Incident at Yauricocha Mine in Peru

Posted on by [email protected]

Research, News, and Market Data on SMTS

SEPTEMBER 12, 2022

TORONTO–(BUSINESS WIRE)– Sierra Metals Inc. (TSX: SMT) (BVL or Bolsa de Valores de Lima: SMT) (NYSE AMERICAN: SMTS) (“Sierra Metals” or “the Company”) regrets to report that at approximately 4:00 PM Lima Time on Sunday September 11, 2022, there was a mudslide incident at its underground Yauricocha Mine, located in Peru.

As a result, three contractor employees lost their lives and one was injured.

The safety and wellbeing of all employees and contractors is a major commitment and focus of the Company, and all efforts are being deployed to ensure them. Mining operations have been temporarily suspended as a result and will resume once conditions are considered safe and appropriate.

Local authorities have been notified and are conducting an investigation into the incident. The Company will provide any updates as they become available.

The thoughts of the board of directors and management are with the family, friends and colleagues that have been impacted by this unfortunate incident.

About Sierra Metals

Sierra Metals Inc. is a diversified Canadian mining company with Green Metal exposure including increasing copper production and base metal production with precious metals byproduct credits, focused on the production and development of its Yauricocha Mine in Peru, and Bolivar and Cusi Mines in Mexico. The Company is focused on increasing production volume and growing mineral resources. Sierra Metals has recently had several new key discoveries and still has many more exciting brownfield exploration opportunities at all three Mines in Peru and Mexico that are within close proximity to the existing mines. Additionally, the Company also has large land packages at all three mines with several prospective regional targets providing longer-term exploration upside and mineral resource growth potential.

The Company’s Common Shares trade on the Bolsa de Valores de Lima and on the Toronto Stock Exchange under the symbol “SMT” and on the NYSE American Exchange under the symbol “SMTS”.

For further information regarding Sierra Metals, please visit www.sierrametals.com

Continue to Follow, Like and Watch our progress:

Web: www.sierrametals.com | Twitter: sierrametals | Facebook: SierraMetalsInc | LinkedIn: Sierra Metals Inc | Instagram: sierrametals

Forward-Looking Statements

This press release contains forward-looking information within the meaning of Canadian and United States securities legislation. Forward-looking information relates to future events or the anticipated performance of Sierra and reflect management’s expectations or beliefs regarding such future events and anticipated performance based on an assumed set of economic conditions and courses of action. In certain cases, statements that contain forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes” or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, or “will be taken”, “occur” or “be achieved” or the negative of these words or comparable terminology. By its very nature forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual performance of Sierra to be materially different from any anticipated performance expressed or implied by such forward-looking information.

Forward-looking information is subject to a variety of risks and uncertainties, which could cause actual events or results to differ from those reflected in the forward-looking information, including, without limitation, the risks described under the heading “Risk Factors” in the Company’s annual information form dated March 16, 2022 for its fiscal year ended December 31, 2021 and other risks identified in the Company’s filings with Canadian securities regulators and the United States Securities and Exchange Commission, which filings are available at www.sedar.com and www.sec.gov, respectively.

The risk factors referred to above are not an exhaustive list of the factors that may affect any of the Company’s forward-looking information. Forward-looking information includes statements about the future and is inherently uncertain, and the Company’s actual achievements or other future events or conditions may differ materially from those reflected in the forward-looking information due to a variety of risks, uncertainties and other factors. The Company’s statements containing forward-looking information are based on the beliefs, expectations, and opinions of management on the date the statements are made, and the Company does not assume any obligation to update such forward-looking information if circumstances or management’s beliefs, expectations or opinions should change, other than as required by applicable law. For the reasons set forth above, one should not place undue reliance on forward-looking information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005688/en/

Investor Relations
Sierra Metals Inc.
+1 (416) 366-7777
Email: [email protected]

Luis Marchese
CEO
Sierra Metals Inc.
+1(416) 366-7777

Source: Sierra Metals Inc.

Release – Bowlero Corp. to Report Fourth Quarter and Full Year 2022 Financial Results

Posted on by [email protected]

Research, News, and Market Data on BOWL

09/12/2022

Prepared remarks to be webcast at 4:30 PM ET on September 15

RICHMOND, Va.–(BUSINESS WIRE)– Bowlero Corp. (NYSE: BOWL) (“Bowlero” or the “Company”), the world’s largest owner and operator of bowling centers, will report financial results for the fourth quarter and full year 2022 on Thursday, September 15, 2022 after the U.S. stock market closes. Management will discuss the results via webcast at 4:30 PM ET on the same day.

The live webcast, replay and results presentation will be accessible in the Events & Presentations section of the Bowlero Investor Relations website at https://ir.bowlerocorp.com/overview/default.aspx.

About Bowlero Corp.

Bowlero Corp. is the worldwide leader in bowling entertainment, media, and events. With more than 300 bowling centers across North America, Bowlero Corp. serves more than 26 million guests each year through a family of brands that includes Bowlero, Bowlmor Lanes, and AMF. In 2019, Bowlero Corp. acquired the Professional Bowlers Association, the major league of bowling, which boasts thousands of members and millions of fans across the globe. For more information on Bowlero Corp., please visit BowleroCorp.com.

For Media:
ICR, Inc.
Tom Vogel
[email protected]

For Investors:
ICR, Inc.
Ashley DeSimone
[email protected]

Source: Bowlero Corp.

Release – InPlay Oil Corp. Announces Participation in Noble Capital Markets C-Suite Interview Series

Posted on by [email protected]

Research, News, and Market Data on IPOOF

September 12, 2022 09:00 ET | Source: InPlay Oil Corp.

CALGARY, Alberta, Sept. 12, 2022 (GLOBE NEWSWIRE) — InPlay Oil Corp. (TSX: IPO) (OTCQX: IPOOF) (“InPlay” or the “Company”) today announced their participation in Noble Capital Markets’ C-Suite Interview Series, presented by Channelchek.

InPlay Oil (IPOOF)(IPO.V) President & CEO Doug Bartole sat down with Noble Capital Markets Senior Research Analyst Michael Heim for this exclusive interview. Topics covered include:

  • How has InPlay reacted to recent energy sector strength?
  • How have drilling costs been affected by inflation and increased production?
  • Behind the decision to raise their credit facility while paying down debt
  • The current acquisition landscape
  • How sustainable are the current oil prices?
  • Why is InPlay an attractive way to invest in the energy space?

The interview was recorded on August 30, 2022 and is available now on Channelchek.

About InPlay Oil Corp.

InPlay is a junior oil and gas exploration and production company with operations in Alberta focused on light oil production. The company operates long-lived, low-decline properties with drilling development and enhanced oil recovery potential as well as undeveloped lands with exploration possibilities. The common shares of InPlay trade on the Toronto Stock Exchange under the symbol IPO and the OTCQX Exchange under the symbol IPOOF.

About Noble Capital Markets

Noble Capital Markets, Inc. was incorporated in 1984 as a full-service SEC / FINRA registered broker-dealer, dedicated exclusively to serving underfollowed small / microcap companies through investment banking, wealth management, trading & execution, and equity research activities. Over the past 37 years, Noble has raised billions of dollars for these companies and published more than 45,000 equity research reports. www.noblecapitalmarkets.com email: [email protected].

About Channelchek
Channelchek (.com) is a comprehensive investor-centric portal – featuring more than 6,000 emerging growth companies – that provides advanced market data, independent research, balanced news, video webcasts, exclusive c-suite interviews, and access to virtual road shows. The site is available to the public at every level without cost or obligation. Research on Channelchek is provided by Noble Capital Markets, Inc., an SEC / FINRA registered broker-dealer since 1984. www.channelchek.com email: [email protected]

For further information please contact:

Doug Bartole
President and Chief Executive Officer
InPlay Oil Corp.
Telephone: (587) 955-0632		 Darren Dittmer
Chief Financial Officer
InPlay Oil Corp.
Telephone: (587) 955-0634